Abstract
Over the last decade, the drug delivery industry has evolved to become a key area in the development of value added pharmaceutical products. The global market grew from $15bn to $40bn during 2000-2006 as companies increasingly turned to drug delivery technologies as a means of expanding product lifecycles, enhancing drug efficacy and maximizing revenues. Although the market is still dominated by the oral drug delivery system, a number of novel technologies are emerging across all systems of delivery. However, the pure drug delivery company model is rapidly becoming extinct as leading players attempt to consolidate their strategic opportunities by expanding their focus towards manufacturing, a trend that is expected to accelerate over the next five years. ' Leading Drug Delivery Companies and Technologies' is a new report published by Business Insights that examines the current and future trends that are shaping the drug delivery market and reviews the key emerging technologies across major systems of drug delivery. This report identifies the product portfolios and targeted therapeutic areas of leading drug delivery companies in addition to assessing their technology platforms to provide guidance over their applicability, regulatory implications and developmental progress. This report also evaluates the opportunities and threats facing each of the companies profiled and provides a comparative analysis of the growth strategies used to facilitate successful deals and collaborations. Identify key trends and developments in the global drug delivery market, assess the performances and portfolios of leading drug delivery companies and benchmark their most successful strategies.
Table of Contents
Executive Summary
- Overview on drug delivery industry
- Oral drug delivery system
- Injectable drug delivery system
- Pulmonary drug delivery system
- Transdermal drug delivery system
Chapter 1 Overview of drug delivery
- industry
- Summary
- What is this report about?
- Methodology
- Drug delivery overview
- Role of drug delivery in the pharma landscape
- Revenue boosters for pharma companies
- Patent extension and protection from generic competition
- Reformulation of existing products
- Optimizing returns on R&D investment
- Compliance, bioavailability and safety benefits
- From drug delivery to specialty pharma
- Markets for drug delivery systems
- Oral drug delivery system
- Pulmonary
- Injectable
- Transdermal
- Market dynamics
Chapter 2 Oral drug delivery system
- Summary
- Synopsis
- Oral drug delivery technologies
- Technologies for fast-dissolving and taste-masking pills
- Controlled oral drug delivery
- Types of controlled release
- Dynamics of oral drug delivery market
- Biovail
- Key technologies
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Expanding its presence in diverse geographical areas
- Deriving growth from strategic alliances
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Elan
- Key technologies
- NanoCrystal technology
- OCR technology
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Alzheimer' s disease
- Pipeline products
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- SkyePharma
- Key technologies
- Oral drug delivery technologies
- Inhalation technologies
- Insoluble drug delivery (IDD) technology
- Therapeutic focus
- Products portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Focus on building pipeline of products
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Chapter 3 Injectable drug delivery system
- Summary
- Synopsis
- Injectable drug delivery technologies
- Needleless injection device technology
- Sustained/controlled release technology
- PEGylation
- Therapeutic focus
- Dynamics of the injectable drug delivery market
- Alkermes
- Introduction
- Key technologies
- Medisorb injectable technology
- AIR pulmonary drug delivery technology
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Bioject
- Introduction
- Key technologies
- Needle-free injection technology
- Therapeutic Focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Developing clinical research collaborations
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- QLT
- Key technologies
- Atrigel drug delivery system
- PDT
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent company financials
- Growth strategies
- Focus on key therapeutic areas
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Chapter 4 Pulmonary drug delivery system
- Summary
- Synopsis
- Inhaled formulations
- Therapeutic focus
- Dynamics of the pulmonary drug delivery market
- Nektar Therapeutics
- Key technologies
- Dry powder pulmonary technology
- Liquid pulmonary technology
- PEGylation technology
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Shifting focus from drug delivery to become a specialty pharma
- company
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Aradigm
- Key technologies
- AERx pulmonary drug delivery system
- Liposomal Formulations
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- 3M
- Key technologies
- Pulmonary drug delivery technology
- Transdermal drug delivery technology
- Therapeutic focus
- Product portfolio and pipeline candidates
- Growth strategies
- Deals and alliances
Chapter 5 Transdermal drug delivery system
- Summary
- Synopsis
- Transdermal drug delivery technologies
- Passive formulations
- Active formulations
- Therapeutic focus
- Dynamics of the transdermal drug delivery market
- Antares
- Key technologies
- Advanced transdermal delivery
- Injection devices
- Easy Tec fast melt oral disintegrating tablets
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Noven
- Key technologies
- DOT Matrix technology
- Therapeutic focus
- Product portfolio and pipeline candidates
- Recent financial performance
- Growth strategies
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
- Alza
- Key technologies
- D-Trans
- E-Trans
- Macroflux
- Stealth
- Alzamer
- Oros
- Therapeutic focus
- Product portfolio and pipeline candidate
- Deals and alliances
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
Chapter 6 Conclusion
- Financials
- Growth strategies
- Outlook
- Glossary
- Index
List of Figures
- Figure 1.1: Drug delivery technologies are revenue boosters for pharma companies
- Figure 1.2: Procardia XL patent expiry
- Figure 1.3: Cardizem' s reformulation strategy
- Figure 1.4: Compliance, bioavailability and safety benefits via effectice drug delivery
- Figure 1.5: Positioning of key drug delivery companies
- Figure 1.6: Key drug delivery systems market share, 2006
- Figure 2.7: Biovail financial performance, $m, 2003-2007
- Figure 2.8: Biovail SWOT analysis
- Figure 2.9: Elan financial performance, 2003-2007 ($m)
- Figure 2.10: Elan SWOT analysis
- Figure 2.11: SkyePharma financial performance, $m, 2003-2007
- Figure 2.12: SkyePharma SWOT analysis
- Figure 3.13: Alkermes financial performance, 2003-2007
- Figure 3.14: Alkermes SWOT analysis
- Figure 3.15: Bioject financial performance, 2003-2007 ($m)
- Figure 3.16: Bioject SWOT analysis
- Figure 3.17: QLT financial performance, 2003-2007 ($m)
- Figure 3.18: QLT SWOT analysis
- Figure 4.19: Nektar financial performance, 2003-2007 ($m)
- Figure 4.20: Nektar SWOT analysis
- Figure 4.21: Aradigm financial performance, 2003-2007 ($m)
- Figure 4.22: Aradigm SWOT analysis
- Figure 5.23: Antares financial performance, 2003-2007 ($m)
- Figure 5.24: Antares SWOT analysis
- Figure 5.25: Noven financial performance, 2003-2007 ($m)
- Figure 5.26: Noven SWOT analysis
- Figure 5.27: Alza SWOT analysis
- Figure 6.28: Comparative analysis of key drug delivery companies (I)
- Figure 6.29: Comparative analysis of key drug delivery companies (II)
List of Tables
- Table 2.1: Biovail snapshot
- Table 2.2: Biovail oral marketed products
- Table 2.3: Biovail oral product sales, 2006-2007 ($m)
- Table 2.4: Biovail oral product pipeline
- Table 2.5: Biovail financial performance, 2003-2007 ($m)
- Table 2.6: Elan snapshot
- Table 2.7: Elan oral marketed products
- Table 2.8: Elan NanoCrystal product pipeline
- Table 2.9: Elan financial performance, 2003-2007 ($m)
- Table 2.10: SkyePharma snapshot
- Table 2.11: SkyePharma oral marketed products
- Table 2.12: Skye Pharma oral product pipeline
- Table 2.13: SkyePharma financial performance, 2003-2007
- Table 3.14: Alkermes snapshot
- Table 3.15: Alkermes injectable marketed products
- Table 3.16: Alkermes injectable product sales, 2006-2007 ($m)
- Table 3.17: Alkermes injectable product pipeline
- Table 3.18: Alkermes financial performance, 2003-2007 ($m)
- Table 3.19: Bioject snapshot
- Table 3.20: Bioject injectable marketed products
- Table 3.21: Bioject injectable product sales, 2006-2007 ($m)
- Table 3.22: Bioject financial performance, 2003-2007 ($m)
- Table 3.23: QLT snapshot
- Table 3.24: QLT injectable marketed products
- Table 3.25: QLT injectable product sales, 2006-2007 ($m)
- Table 3.26: QLT injectable product pipeline
- Table 3.27: QLT financial performance, 2003-2007 ($m)
- Table 4.28: Nektar snapshot
- Table 4.29: Nektar pulmonary marketed products
- Table 4.30: Nektar pulmonary product sales, 2006-2007 ($m)
- Table 4.31: Nektar pulmonary product pipeline
- Table 4.32: Nektar financial performance, 2003-2007 ($m)
- Table 4.33: Aradigm snapshot
- Table 4.34: Aradigm pulmonary product pipeline
- Table 4.35: Aradigm financial performance, 2003-2007 ($m)
- Table 4.36: 3M snapshot
- Table 4.37: 3M pulmonary marketed products
- Table 5.38: Antares snapshot
- Table 5.39: Antares transdermal marketed products
- Table 5.40: Antares transdermal product pipleine
- Table 5.41: Antares financial performance, 2003-2007 ($m)
- Table 5.42: Noven snapshot
- Table 5.43: Noven transdermal marketed products
- Table 5.44: Noven transdermal product pipeline
- Table 5.45: Noven financial performance, 2003-2007 ($m)
- Table 5.46: Alza snapshot
- Table 5.47: Alza transdermal marketed products
